



Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Registered Office:

3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6,
Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills,
Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000,

E: investorrelations@viyash.com

Website: www.viyash.com

CIN: L99999TS1985PLC196357

May 19, 2026

To,

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

National Stock Exchange of India Limited

Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East),
Mumbai - 400 051

Scrip code: 512529

Scrip code: VIYASH

Dear Sir/ Madam,

Subject: Press Release for Q4 FY 2025-26

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Press Release on Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026.

This is for your information and appropriate dissemination.

Thanking you,

Yours faithfully,

For **Viyash Scientific Limited**

(Formerly known as Sequent Scientific Limited)

Yoshita Vora

Company Secretary & Compliance Officer



Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000, E:info@viyash.com

E: investorrelations@viyash.com

Website: www.viyash.com CIN: L99999TS1985PLC196357

Q4 FY26 – The strongest quarter in Company's history- EBITDA* surpasses Rs. 200 Cr. FY 26- EBITDA* up by 59.6% and PAT by 1324% with robust free cash flow and Strong foundation for future growth.

Highlights

Q4 FY26 – Revenues at ₹ 9,200 Million up by 19.1%, EBITDA* at ₹ 2,001 Million up 63.8 %

FY26 – Revenues at ₹ 34,203 Million up by 13.8%, EBITDA* at ₹ 7,025 Million up 59.6%

Q4 FY 26 PAT at ₹ 664 Million, up by 306%

FY 26 PAT at ₹ 2,246 Million, up by 1324%

Net Debt / EBITDA* at 0.2 x



Hyderabad, May 19, 2026

Viyash Scientific Limited (formerly SeQuent Scientific Limited), which has businesses across Formulations, APIs and CDMO Services for Human and Animal health, today announced its financial results for the period ended March 31, 2026.



Consolidated Financial Highlights

₹ in millions

	Q4FY26	Q4FY25	Growth %	FY26	FY25	Growth %
Revenues	9,200	7,723	19.1%	34,203	30,068	13.8%
EBITDA*	2,001	1,221	63.9%	7,025	4,400	59.6%
EBITDA* %	21.7%	15.8%		20.5%	14.6%	
PAT	664	-322	305.5%	2,246	158	1334.0%

EBITDA* refers to EBITDA excluding ESOP costs

Detailed presentation on the performance forms part of this press release

Commenting on the Company's performance, **Dr Hari Babu Bodepudi, Managing Director and Group CEO** stated

"Fiscal Year 2026 has been a transformative year for Viyash Scientific, marked by the successful integration of our facilities, operations, and corporate functions into one unified platform. Q4 was the strongest quarter in the Company's history, with merger synergies beginning to reflect meaningfully in our financial performance. The integrated platform has strengthened execution, improved operating leverage, and enhanced our resilience amidst ongoing geopolitical and maritime disruptions. We continue to navigate these challenges through disciplined asset utilization, cost controls, and agile pricing strategies. As we enter FY27, we are excited about our product pipeline and growth roadmap. With a significantly deleveraged balance sheet, we are also actively evaluating selective inorganic opportunities to further strengthen our platform and create long-term value"



Earnings Call with Investors

The Company will conduct an Earnings call at **16:00 IST on May 20, 2026** where the Management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are **+91 22 6280 1263 or +91 22 7115 8213**

About Viyash Scientific Limited

Viyash Scientific Limited (formerly known as Sequent Scientific Limited) headquartered in India is globally among top-25 Animal Health companies. With over 3,000 talented employees, Viyash Scientific Limited is an integrated pharmaceutical company having a rich portfolio of formulations and APIs for human and veterinary use, serving customers in 100+ countries. Viyash and its subsidiaries have manufacturing, R&D and distribution operations across India, Spain, Brazil, Turkey and USA, with approvals from international regulatory bodies, including USFDA, EUGMP, WHO, TGA, etc.

For details, feel free to contact

Yoshita Vora

Company Secretary, Tel: +91 22 4111 4717

investorrelations@viyash.com

Abhishek Singhal

Investor Relations Consultants

abhishek@arunya.co.in

Registered Office

3rd Floor, Srivalli's Corporate,

Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills,

Shaikpet, Hyderabad-500033, Telangana

CIN: L99999TS1985PLC196357

BSE Code: 512529 INSE: VIYASH

ISIN: INE807F01027 I REUTERS: EQU.BO

Website: www.viyash.com

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. Viyash Scientific Ltd. will not be responsible in any way for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstance.